ND-630

• CAT Number: I008264
• CAS Number: 1434635-54-7
• Molecular Formula: C28H31N3O8S
• Molecular Weight: 569.629
• Purity: ≥95%
• Synonyms: ND-630; ND 630; ND630. NDI-010976; NDI 010976; NDI010976.;1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-α,α,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid
• Target: Acetyl-CoA Carboxylase
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C28H31N3O8S/c1-16-21-24(32)31(28(2,3)26(33)34)27(35)30(25(21)40-22(16)23-29-11-14-38-23)15-20(39-17-9-12-37-13-10-17)18-7-5-6-8-19(18)36-4/h5-8,11,14,17,20H,9-10,12-13,15H2,1-4H3,(H,33,34)/t20-/m0/s1
• InChIKey: ZZWWXIBKLBMSCS-FQEVSTJZSA-N
• SMILES: O=C(O)C(C)(C)N(C(N(C[C@@H](C1=CC=CC=C1OC)OC2CCOCC2)C3=C4C(C)=C(C5=NC=CO5)S3)=O)C4=O

ND-630 (CAT: I008264), also referred to as NDI-010976, is a potent inhibitor of acetyl-CoA carboxylase (ACC). This compound effectively disrupts the dimerization and enzymatic activity of both ACC isozymes by binding within the ACC phosphopeptide acceptor and dimerization site. By doing so, ND-630 efficiently reduces the synthesis of fatty acids and promotes their oxidation in both cultured cells and animal models. This unique mode of action has demonstrated the ability to modulate cellular lipid metabolism.

Reference

1:Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1796-805. doi: 10.1073/pnas.1520686113. Epub 2016 Mar 14. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.Harriman G,Greenwood J,Bhat S,Huang X,Wang R,Paul D,Tong L,Saha AK,Westlin WF,Kapeller R,Harwood HJ Jr, PMID: 26976583 PMCID: PMC4822632 DOI: 10.1073/pnas.1520686113 Abstract: Simultaneous inhibition of the acetyl-CoA carboxylase (ACC) isozymes ACC1 and ACC2 results in concomitant inhibition of fatty acid synthesis and stimulation of fatty acid oxidation and may favorably affect the morbidity and mortality associated with obesity, diabetes, and fatty liver disease. Using structure-based drug design, we have identified a series of potent allosteric protein-protein interaction inhibitors, exemplified by ND-630, that interact within the ACC phosphopeptide acceptor and dimerization site to prevent dimerization and inhibit the enzymatic activity of both ACC isozymes, reduce fatty acid synthesis and stimulate fatty acid oxidation in cultured cells and in animals, and exhibit favorable drug-like properties. When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. When administered chronically to Zucker diabetic fatty rats, ND-630 reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c (0.9% reduction). Together, these data suggest that ACC inhibition by representatives of this series may be useful in treating a variety of metabolic disorders, including metabolic syndrome, type 2 diabetes mellitus, and fatty liver disease.